Notch Transduction in Non-Small Cell Lung Cancer

被引:36
|
作者
Sharif, Amnah [1 ]
Shaji, Ann [1 ]
Chammaa, May [1 ,2 ]
Pawlik, Eileen [1 ]
Fernandez-Valdivia, Rodrigo [1 ,3 ,4 ,5 ]
机构
[1] Wayne State Univ, Dept Pathol, Sch Med, Detroit, MI 48201 USA
[2] Wayne State Univ, Doctor Med Program, Sch Med, Detroit, MI 48201 USA
[3] Wayne State Univ, Dept Oncol, Sch Med, Detroit, MI 48201 USA
[4] Wayne State Univ, Canc Biol Grad Program, Sch Med, Detroit, MI 48201 USA
[5] Barbara Ann Karmanos Canc Inst, Tumor Biol & Microenvironm Program, Detroit, MI 48201 USA
关键词
Notch signaling; lung cancer; non-small cell lung cancer; lung development; lung cancer therapy; GAMMA-SECRETASE INHIBITOR; PULMONARY NEUROENDOCRINE CELLS; SIGNALING PATHWAY; STEM-CELLS; PHASE-I; EPITHELIAL DIFFERENTIATION; PROGNOSTIC MARKER; MUCOUS METAPLASIA; TUMOR-SUPPRESSOR; GROWTH;
D O I
10.3390/ijms21165691
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The evolutionarily-conserved Notch signaling pathway plays critical roles in cell communication, function and homeostasis equilibrium. The pathway serves as a cell-to-cell juxtaposed molecular transducer and is crucial in a number of cell processes including cell fate specification, asymmetric cell division and lateral inhibition. Notch also plays critical roles in organismal development, homeostasis, and regeneration, including somitogenesis, left-right asymmetry, neurogenesis, tissue repair, self-renewal and stemness, and its dysregulation has causative roles in a number of congenital and acquired pathologies, including cancer. In the lung, Notch activity is necessary for cell fate specification and expansion, and its aberrant activity is markedly linked to various defects in club cell formation, alveologenesis, and non-small cell lung cancer (NSCLC) development. In this review, we focus on the role this intercellular signaling device plays during lung development and on its functional relevance in proximo-distal cell fate specification, branching morphogenesis, and alveolar cell determination and maturation, then revise its involvement in NSCLC formation, progression and treatment refractoriness, particularly in the context of various mutational statuses associated with NSCLC, and, lastly, conclude by providing a succinct outlook of the therapeutic perspectives of Notch targeting in NSCLC therapy, including an overview on prospective synthetic lethality approaches.
引用
收藏
页码:1 / 27
页数:27
相关论文
共 50 条
  • [31] SURGERY FOR NON-SMALL CELL LUNG CANCER
    Vrtik, Marosh
    Alam, Naveed Z.
    CANCER FORUM, 2013, 37 (02) : 150 - 153
  • [32] Oligoprogression in Non-Small Cell Lung Cancer
    Harada, Daijiro
    Takigawa, Nagio
    CANCERS, 2021, 13 (22)
  • [33] Screening for non-small cell lung cancer
    Ashton, RW
    Jett, JR
    SEMINARS IN ONCOLOGY, 2005, 32 (03) : 253 - 258
  • [34] Immunotherapy for non-small cell lung cancer
    Vafadar, Sam
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (09): : 37 - 42
  • [35] The lymphadenectomy in non-small cell lung cancer
    Chiappetta, Marco
    VIDEO-ASSISTED THORACIC SURGERY, 2022, 7
  • [36] Paclitaxel for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (08) : 1771 - 1780
  • [37] Immunotherapy in non-small cell lung cancer
    Peters, Geoffrey
    John, Thomas
    CANCER FORUM, 2018, 42 (01) : 24 - 28
  • [38] Pneumonectomy for non-small cell lung cancer
    Ichiki, Yoshinobu
    Nagashima, Akira
    Chikaishi, Yasuhiro
    Yasuda, Manabu
    SURGERY TODAY, 2012, 42 (09) : 830 - 834
  • [39] METASTASE IN NON-SMALL CELL LUNG CANCER
    Luan Van Pham
    Tien Dinh Nguyen
    Hai Minh Nguyen
    Tien Dao Nguyen
    Duyen Thi Thi
    Son Van Nguyen
    Dai Van Tran
    RESPIROLOGY, 2019, 24 : 272 - 272
  • [40] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270